tbuckley/cabot-search huggingface dataset:
PTU-054 Transjugular intrahepatic portosystemic shunts following liver transplantation can be associated with a good prognosis: a single centre experience
Authors: B Hogan, D Thorburn, D Sharma, B Davidson, J P O'Beirne, A K Burroughs, D Yu, D W Patch
Journal: Gut (2012)

<h3>Introduction</h3> Transjugular intrahepatic portosystemic shunt (TIPS) is indicated in the management of portal vein thrombosis or stenosis, portal hypertension and for veno-occlusive disease in post-liver transplant (LT) patients. Previous series have reported 1-year mortality rates of 14%–67%. A MELD score &gt;15 at the time of insertion may indicate a poor long term prognosis. We aimed to evaluate the safety of TIPS after LT at a UK tertiary referral centre. <h3>Methods</h3> We retrospectively analysed data from the Royal Free Hospital TIPS database between 1st January 1991 and the 31st January 2011. All patients who had undergone TIPS following LT were included. <h3>Results</h3> During the period studied 629 patients received a TIPS. In the same period 1192 liver transplant operations were performed. 10 TIPS were inserted into patients following LT for recurrent cirrhosis with refractory ascites (4), veno-occlusive disease (3) and portal vein thrombosis (3). The original indications for transplantation were PSC (3), PBC (3), Hepatitis C (1), Autoimmune (1), Primary Oxalosis (1) and Acute Liver Failure (1). We noted a median survival of 38 months. Survival at 1 and 5 years was 100% and 60% respectively. The median MELD at the time of TIPS insertion was 12 (range 7–19). No correlation between the MELD score at the time of TIPS insertion and survival was demonstrated (p=0.62). <h3>Conclusion</h3> These results suggest that TIPS can be performed safely after LT and that survival rates better than those previously reported can be achieved. We suggest TIPS should be used in carefully selected candidates following LT as a definitive treatment for patients not suitable for re-transplant or as a bridge to re-transplantation. The alternative of re-transplantation should always be considered prior to TIPS insertion where indicated. <h3>Competing interests</h3> None declared. <h3>References</h3> 1. <b>Saad WEA</b>, <i>et al.</i> Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome. <i>J Vasc Interv Radiol</i> 2010;<b>21</b>:218–23. 2. <b>Kim JJ</b>, <i>et al.</i> Transjugular intrahepatic portosystemic shunts in liver transplant recipients. <i>Liver Int</i> 2008;<b>28</b>:240–8. 3. <b>Feyssa E</b>, <i>et al.</i> MELD score less than 15 predicts prolonged survival after transjugular intrahepatic portosystemic shunt for refractory ascites after liver transplantation. <i>Transplantation</i> 2011;<b>91</b>:786–92.
Assessment of Baveno VI and expanded Baveno VI criteria for screening and follow-up of all-size esophageal varices in patients with compensated viral cirrhosis (ANRS/CO12 CirVir cohort)
Authors: Charlotte Bouzbib, Pierre Nahon, Layese Richard, Tarik Asselah, Dominique Guyader, Stanislas Pol, Etienne Audureau, Françoise Roudot-Thoraval, Dominique Thabut
Journal: Journal of Hepatology (2020)
Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs
Authors: Z. Vajo
Journal: Endocrine Reviews (2001)

After more than half a century of treating diabetics with animal insulins, recombinant DNA technologies and advanced protein chemistry made human insulin preparations available in the early 1980s. As the next step, over the last decade, insulin analogs were constructed by changing the structure of the native protein with the goal of improving the therapeutic properties of it, because the pharmacokinetic characteristics of rapid-, intermediate-, and long-acting preparations of human insulin make it almost impossible to achieve sustained normoglycemia. The first clinically available insulin analog, lispro, confirmed the hopes by showing that improved glycemic control can be achieved without an increase in hypoglycemic events. Two new insulin analogs, insulin glargine and insulin aspart, have recently been approved for clinical use in the United States, and several other analogs are being intensively tested. Thus, it appears that a rapid acceleration of basic and clinical research in this arena will be seen, which will have direct significance to both patients and their physicians. The introduction of new short-acting analogs and the development of the first truly long-acting analogs and the development of analogs with increased stability, less variability, and perhaps selective action, will help to develop more individualized treatment strategies targeted to specific patient characteristics and to achieve further improvements in glycemic control. Data on the currently available and tested analogs, as well as data on those currently being developed, are reviewed.
Fortschr Roentgenstr &amp;amp; Nuklearmed, Stuttgart
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevention starts in kindergarten in New York City
Authors: T. F. Kirn
Journal: JAMA (1988)

THE OLD HEALTH curriculum used in the elementary schools in New York City contained a section on lawn mower safety; pretty ludicrous for a city where most grass grows either in the parks or in a crack in the sidewalk, according to Dale Mann, PhD. In fact, Mann, a professor at Columbia University's Teachers' College, has nothing nice to say about that curriculum: "It was real cognitive and real preachy. It was not something I would want my son exposed to." Reportedly, the teachers were ill-prepared to teach the subject, so they had little motivation to use the curriculum. Too many times, they ignored it completely. "Whatever the teacher taught" in effect became the curriculum, says Peggy Tumminio, assistant director, Office of Health, Physical Education and School Sports, New York City Board of Education. Now, the children there have a new, more rigorous health education program. "Growing Healthy in New
<i>Erratum:</i> Vol. 70, No. 32
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

In the report "Racial and Ethnic Disparities in Breastfeeding Initiation -United States, 2019," on page 774, the last sentence should have read, "Implementation of evidencebased maternity care policies and practices supportive of breastfeeding and targeted breastfeeding programs focusing on populations at highest risk for low breastfeeding initiation might help reduce racial/ethnic disparities in breastfeeding initiation, improve infant nutrition, and reduce maternal and infant morbidity."
Reply
Authors: Giovanni A. Fava
Journal: Psychotherapy and Psychosomatics (2003)

Letters| March 03 2003 Reply Subject Area: Psychiatry and Psychology Giovanni A. Fava Giovanni A. Fava Dipartimento di Psicologia, Università degli Studi di Bologna, Italia Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (2003) 72 (2): 109. https://doi.org/10.1159/000068685 Article history Published Online: March 03 2003 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Giovanni A. Fava; Reply. Psychother Psychosom 1 April 2003; 72 (2): 109. https://doi.org/10.1159/000068685 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 2003Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.
Memoir of a surgical nutritionist
Authors: J. E. Rhoads
Journal: JAMA (1994)

To begin to describe my introduction to medicine, I would like to resurrect some childhood memories. My earliest distinct memory was of being taken at the age of 4 years into my father's medical office, which was in our home, and being weighed. I weighed 44 pounds—a number I can perhaps record as my earliest piece of nutritional research. It certainly was not original, but at least it was quantitative. When I was 11 years of age, an older sister who was studying chemistry was retained by my father to run urinalyses. I was in the office watching her when she added Fehling's solution to a urine specimen that, when boiled, brought down a heavy precipitate. My father came in, examined the results, and looked extremely grave; I was told this meant the patient had diabetes mellitus and probably would not live 2 years. This was in 1918 before the
SALE OF PREPARATIONS CONTAINING POISONS.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Doxycycline Treatment and Desert Storm
Authors: Nancy L. Rosenberg-Nicolson
Journal: JAMA (1995)

<h3>To the Editor.</h3> —If the National Institutes of Health (NIH) Technology Assessment Workshop report on Operation Desert Storm syndrome/illnesses was meant to address fears that these illnesses are not being taken seriously and to establish practical working case definitions for the chronic illnesses associated with Operations Desert Shield and Desert Storm, it was not an auspicious start. After listening to the health complaints of numerous veterans of Operations Desert Shield and Desert Storm, including our stepdaughter and her colleagues who served in the US Army's 101st Airborne Division, and complaints about their inability to convince military hospitals and Veterans Affairs medical centers that they are suffering from a possible syndrome with the same major symptoms listed in the workshop report, we attempted to suggest that many of these symptoms can be explained by aggressive pathogenic mycoplasma infections, such as<i>Mycoplasma incognitus or Mycoplasma penetrans</i>,<sup>2</sup>and they should be treatable
SCHOOLS IN THEIR EFFECTS ON THE HEALTH OF GROWING GIRLS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications
Journal: Journal of Clinical Investigation (1993)

Because of a publisher's error, the following changes should be made in the text: Page 630, left hand column, line 4, should read: ". . .equilibrium Kd of 1.5 nM as a nominal value. .Page 631, Table I: the column heading that now reads "GH bound to protein" should read "
Significance of neutrophil activation in reactional lepromatous leprosy: Effects of thalidomide in vivo and in vitro. Activation in adjuvant disease Yahr, M.G., Convit, J., Rodriguez-Ochoa, G., Aranzazu, N., Villalba-Pimentel, L., Ocanto, A., and deGomez, M.: Int. Arch. Allergy Appl. Immunol. 57:317, 1978
Journal: Journal of Allergy and Clinical Immunology (1979)
A tax on luxury: HTLV-I infection of CD4+CD25+ Tregs
Authors: R. S. Fujinami
Journal: Journal of Clinical Investigation (2005)

Almost a quarter of a century ago, Oldstone and colleagues proposed that infection of cells by noncytopathic viruses may lead to an alteration of the cells’ ability to produce certain products or perform certain tasks, i.e., inhibition of “luxury function.” In this issue of the JCI, this topic has been revisited by Yamano et al., who demonstrate that human T cell lymphotropic virus type I (HTLV-I) infection of CD4+CD25+ Tregs in patients with HTLV-I–associated myelopathy/tropical spastic paraparesis (HAM/TSP) results in a decrease in FOXP3 mRNA and protein expression. This leads to the inability of HTLV-I–infected CD4+CD25+ Tregs to inhibit the proliferation of CD4+CD25− Tregs, due to the effect of the HTLV-I tax gene. Defects in the Treg population could be responsible for the large numbers of virus-specific T cells and occurrence of lymphoproliferation and inflammatory autoimmune disease in HAM/TSP patients.
Public health advocates target children's health
Authors: R. Voelker
Journal: JAMA (1996)

AS THE 1900s slip into history, public health experts want to battle children's health threats with the same tenacity— and success—as they fought infectious diseases at the turn of the last century. During its recent annual meeting in New York City, the American Public Health Association (APHA) called on President Clinton and Congress to develop a universal health care program for children, and it offered recommendations to help create such a program. E. Richard Brown, PhD, immediate past president of APHA, called the proposal "urgent and feasible." The feasibility lies in using existing options such as Medicaid waivers to achieve universal coverage for children, without extensive new programming or cost. Urgency, Brown said, is a by-product of the new welfare law that reduces cash and food stamp benefits while throwing several facets of Medicaid eligibility into question. He cited an estimate by the Urban Institute in Washington, DC, that the
Tetanus
Authors: Henry Brown
Journal: JAMA (1968)

Tetanus is a dread infection written about since ancient times. It is known and described chiefly because of the severe toxic effect of the exotoxin of the causative anaerobic organism,<i>Clostridium tetani</i>. <h3>Onset of Symptoms</h3> Infection may follow a trivial, forgotten injury. More often it follows a severe, contaminated, crushing type of wound. The incubation period is usually stated as 7 to 21 days, but the infection frequently occurs in less time. Prognosis becomes less favorable as incubation time shortens and mortality rises sharply when it is less than 10 days. Formerly, the outlook for younger patients with tetanus infection was better than for older patients, but this may no longer be true. In an earlier series from the Boston City Hospital from 1930 to 1947, ten of 17 tetanus patients under 12 years of age recovered, whereas all the ten patients over 12 years of age died (Table 1).
Hidden Diabetes in the UK: Use of Capture-Recapture Methods to Estimate total Prevalence of Diabetes Mellitus in an Urban Population
Authors: Geoffrey V Gill, Aziz A Ismail, Nicholas J Beeching, Sarah B J Macfarlane, Mark A Bellis
Journal: Journal of the Royal Society of Medicine (2003)

An early requirement of the UK's Diabetes National Service Framework is enumeration of the total affected population. Existing estimates tend to be based on incomplete lists. In a study conducted over one year in North Liverpool, we compared crude prevalence rates for type 1 and type 2 diabetes with estimates obtained by capture-recapture (CR) analysis of multiple incomplete patient lists, to assess the extent of unascertained but diagnosed cases. Patient databases were constructed from six sources-a hospital diabetes centre; general practitioner registers; hospital admissions with a diagnosis of diabetes; a hospital diabetic retinal clinic; a research list of patients with diabetes admitted with stroke; and a local children's hospital. Log linear modelling was used to estimate missing cases, hence total prevalence. The crude prevalence of diabetes was 1.5% (95% confidence interval [CI] 1.41, 1.52), compared with a CR-adjusted rate of 3.1% (CI 3.03, 3.19). Age-banded CR-adjusted prevalence was always higher in males than in females and the difference became more pronounced with increasing age. Among males, CR-adjusted prevalence rose from 0.4% at age 10-19 years to 18.3% at 80+ years; in females the corresponding figures were 0.4% and 9.3%. The gap between crude and CR-estimated prevalence points to a rate of 'hidden diabetes' that has substantial implications for future diabetes care.
Reproductive Health Care Manual
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Joint Study of Extracranial Arterial Occlusion
Authors: William S. Fields
Journal: JAMA (1970)

A series of 316 patients with transient cerebral ischemic attacks and no neurological deficit were randomly allocated to surgical or nonsurgical treatment categories in a controlled manner. The total group was divided by anatomical patterns of lesions (carotid stenosis, unilaterally; carotid stenosis, bilaterally; and unilateral occlusion with opposite stenosis). During an average 42-month follow-up, distinct differences in outcome were noted in specific subgroups in the frequency and pattern of transient attacks and in the occurrence and location of cerebral infarction.
Topspin
Authors: George N. Braman
Journal: Annals of Internal Medicine (2004)

Ad Libitum18 May 2004TopspinGeorge N. Braman, MDGeorge N. Braman, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-10-200405180-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Topspin: “a fast forward spinning motion imparted to a ball in tennis, by hitting it forward and upward”–The Oxford Dictionary and Thesaurus... Author, Article, and Disclosure InformationAuthors: George N. Braman, MDCurrent Author Address: George N. Braman, MD, 6142 Delafield Avenue, Bronx, NY 10471. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPerceived Impact of Duty Hours Regulations: A Survey of Residents and Program DirectorsA case for the 80 duty-hour week 18 May 2004Volume 140, Issue 10 Page: 843 Keywords Mortality Sports ePublished: 18 May 2004 Issue Published: 18 May 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...